The Inivata Radar Assay: A Highly Sensitive and Specific ctDNA Assay for the Detection of Molecular Residual and Recurrent Disease

Minimal/molecular residual disease (MRD) testing to detect a cancer patient’s circulating tumor DNA (ctDNA) has recently emerged as a powerful and highly personalized addition to population-based disease markers.

Contemporary MRD testing applications include 1) research use only (RUO) assays to aid in biopharmaceutical clinical trial design and execution and 2) laboratory developed tests (LDTs) to support clinical decisionmaking through the early detection and serial monitoring of ctDNA among individual cancer patients.

The purpose of this white paper is to educate the reader on the relevant characteristics of the Inivata RaDaR Assay, including key features and benefits, assay process, analytical validation, as well as current and potential uses as an RUO assay among stakeholders engaged in biopharmaceutical cancer drug research.

Whitepaper

Complete the form below to download the content.

* - marks a required field

Email Address

First Name

Last Name

Address

City

Country

State

Post Code

Phone

Answer the following questions about your organization below:

Company Name

How many people are employed by your organization?

What is your company's revenue?

In which industry do you work?

Job Title

Job Level

By clicking ‘Submit’ you agree to our Terms of Use. We take your privacy seriously. For more information please read our Privacy Policy.